Oxidative stress in genetic mouse models of Parkinsons disease

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2012, Pages

  Varin, Mustafa ^a   Bentea, Eduard ^a   Michotte, Yvette ^a   Sarre, Sophie ^a  

^a FACULTY OF MEDICINE AND PHARMACY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC MECHANISM; COMPLEX INTERACTION; ENVIRONMENTAL FACTORS; ENVIRONMENTAL STRESS; GENE-ENVIRONMENT INTERACTION; GENETIC MAKE-UP; MITOCHONDRIAL DYSFUNCTION; MOUSE MODELS; NEUROINFLAMMATION; NEURONAL FUNCTION; OXIDATIVE DAMAGE; PARKINSONS DISEASE; PATHOGENIC PATHWAYS; POTENTIAL IMPACTS;

GENES; GENETIC ENGINEERING; MACHINERY; MAMMALS;

OXIDATIVE STRESS;

ANTIOXIDANT ACTIVITY; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DJ 1 GENE; GENE; GENETIC ENGINEERING; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKIN GENE; PARKINSON DISEASE; PINK1 GENE; REVIEW; RISK FACTOR; SNCA GENE; ANIMAL; BIOLOGICAL MODEL; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE-ENVIRONMENT INTERACTION; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84864928966     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2012/624925     Document Type: Review

References (173)

1. Obeso J. A., Rodriguez-Oroz M. C., Goetz C. G., Missing pieces in the Parkinson's disease puzzle Nature Medicine 2010 16 6 653 661
2. Crosiers D., Theuns J., Cras P., Van Broeckhoven C., Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes Journal of Chemical Neuroanatomy 2011 42 2 131 141
3. Sundal C., Fujioka S., Uitti R. J., Wszolek Z. K., Autosomal dominant Parkinson's disease Parkinsonism Related Disorders 2012 18, supplement 1 S7 S10
4. Reichmann H., View point: etiology in Parkinson's disease. Dual hit or spreading intoxication Journal of the Neurological Sciences 2011 310 1-2 9 11
5. Lesage S., Brice A., Role of Mendelian genes in sporadic Parkinson's disease Parkinsonism Related Disorders 2012 18, supplement 1 S66 S70
6. Taccioli C., Maselli V., Tegnér J., ParkDB: a Parkinson's disease gene expression database Database 2011 2011, article bar007
7. Shulman J. M., De Jager P. L., Feany M. B., Parkinson's disease: genetics and pathogenesis Annual Review of Pathology 2011 6 193 222
8. Dunning C. J., Can Parkinson's disease pathology be propagated from one neuron to another? Progress in Neurobiology. In press
9. Henchcliffe C., Beal F. M., Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis Nature Clinical Practice Neurology 2008 4 11 600 609
10. Braak H., Del Tredici K., Rb U., De Vos R. A. I., Jansen Steur E. N. H., Braak E., Staging of brain pathology related to sporadic Parkinson's disease Neurobiology of Aging 2003 24 2 197 211 (Pubitemid 36007810)
11. Hawkes C. H., Del Tredici K., Braak H., A timeline for Parkinson's disease Parkinsonism and Related Disorders 2010 16 2 79 84
12. Schapira A. H. V., Neurobiology and treatment of Parkinson's disease Trends in Pharmacological Sciences 2009 30 1 41 47
13. Stocchi F., Olanow C. W., Neuroprotection in Parkinson's disease: clinical trials Annals of Neurology 2003 53 3, supplement S87 S99
14. Yacoubian T. A., Standaert D. G., Targets for neuroprotection in Parkinson's disease Biochimica et Biophysica Acta 2009 1792 7 676 687
15. Blum D., Torch S., Lambeng N., Nissou M. F., Benabid A. L., Sadoul R., Verna J. M., Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease Progress in Neurobiology 2001 65 2 135 172 (Pubitemid 32524182)
16. Aoyama K., Watabe M., Nakaki T., Regulation of neuronal glutathione synthesis Journal of Pharmacological Sciences 2008 108 3 227 238
17. Jenner P., Oxidative stress in Parkinson's disease Annals of Neurology 2003 53, supplement 3 S26 S36
18. Kawajiri S., Saiki S., Sato S., Hattori N., Genetic mutations and functions of PINK1 Trends in Pharmacological Sciences 2011 32 10 573 580
19. Seet R. C. S., Lee C. Y. J., Lim E. C. H., Tan J. J. H., Quek A. M. L., Chong W. L., Looi W. F., Huang S. H., Wang H., Chan Y. H., Halliwell B., Oxidative damage in Parkinson disease: measurement using accurate biomarkers Free Radical Biology and Medicine 2010 48 4 560 566
20. Jenner P., Oxidative mechanisms in nigral cell death in Parkinson's disease Movement Disorders 1998 13 1 24 34
21. Smith M. P., Cass W. A., Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease Neuroscience 2007 144 3 1057 1066 (Pubitemid 46013981)
22. Dawson T. M., Ko H. S., Dawson V. L., Genetic animal models of Parkinson's disease Neuron 2010 66 5 646 661
23. Farrer M. J., Genetics of Parkinson disease: paradigm shifts and future prospects Nature Reviews Genetics 2006 7 4 306 318
24. Horowitz M. P., Greenamyre J. T., Gene-environment interactions in parkinson's disease: the importance of animal modeling Clinical Pharmacology and Therapeutics 2010 88 4 467 474
25. Thomas K. J., Cookson M. R., The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics International Journal of Biochemistry and Cell Biology 2009 41 10 2025 2035
26. Moore D. J., West A. B., Dawson V. L., Dawson T. M., Molecular pathophysiology of Parkinson's disease Annual Review of Neuroscience 2005 28 57 87 (Pubitemid 41098899)
27. Akundi R. S., Zhi L., Bueler H., PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis Neurobiology of Disease 2011 45 1 469 478
28. Diedrich M., Kitada T., Nebrich G., Brain region specific mitophagy capacity could contribute to selective neuronal vulnerability in Parkinson's disease Proteome Science 2011 9 59
29. Gautier C. A., Kitada T., Shen J., Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress Proceedings of the National Academy of Sciences of the United States of America 2008 105 32 11364 11369
30. Deas E., Plun-Faureau H., Wood N. W., PINK1 function in health and disease EMBO Molecular Medicine 2009 1 3 152 165
31. Dalle-Donne I., Giustarini D., Colombo R., Rossi R., Milzani A., Protein carbonylation in human diseases Trends in Molecular Medicine 2003 9 4 169 176 (Pubitemid 36626706)
32. Toulouse A., Sullivan A. M., Progress in Parkinson's disease-Where do we stand? Progress in Neurobiology 2008 85 4 376 392
33. Cui K., Luo X., Xu K., Ven Murthy M. R., Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004 28 5 771 799 (Pubitemid 39195270)
34. Gilgun-Sherki Y., Melamed E., Offen D., Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier Neuropharmacology 2001 40 8 959 975 (Pubitemid 32530602)
35. Mythri R. B., Venkateshappa C., Harish G., Mahadevan A., Muthane U. B., Yasha T. C., Srinivas Bharath M. M., Shankar S. K., Evaluation of Markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains Neurochemical Research 2011 36 8 1452 1463
36. Andersen J. K., Oxidative stress in neurodegeneration: cause or consequence? Nature Medicine 2004 10 S18 S25
37. de Vries H. E., Witte M., Hondius D., Rozemuller A. J. M., Drukarch B., Hoozemans J., van Horssen J., Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radical Biology and Medicine 2008 45 10 1375 1383
38. Fahn S., Cohen G., The oxidant stress hypothesis in Parkinson's disease: evidence supporting it Annals of Neurology 1992 32 6 804 812
39. Youdim M. B., Drigues N., Mandel S., Oxidative stress indices in Parkinson's disease: biochemical determination Methods in Molecular Medicine 2001 62 137 153
40. Ilic T., Jovanovi M., Jovici A., Tomovi M., Oxidative stress and Parkinson's disease Vojnosanitetski Pregled 1998 55 5 463 468
41. Vinish M., Anand A., Prabhakar S., Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations Acta Biochimica Polonica 2011 58 2 165 169
42. Selley M. L., E-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease Free Radical Biology and Medicine 1998 25 2 169 174 (Pubitemid 28293150)
43. Buhmann C., Arlt S., Kontush A., Mller-Bertram T., Sperber S., Oechsner M., Stuerenburg H. J., Beisiegel U., Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication Neurobiology of Disease 2004 15 1 160 170 (Pubitemid 38134391)
44. del Hoyo P., Garca-Redondo A., de Bustos F., Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease BMC Neurology 2011 10 95
45. Byers B., Cord B., Nguyen H. N., SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress PLoS ONE 2011 6 11
46. Bellinger F. P., Bellinger M. T., Seale L. A., Takemoto A. S., Raman A. V., Miki T., Manning-Bo A. B., Berry M. J., White L. R., Ross G. W., Glutathione peroxidase 4 is associated with neuromelanin in substantia nigra and dystrophic axons in putamen of Parkinson's brain Molecular Neurodegeneration 2011 6 1, article 8
47. Migliore L., Copped F., Environmental-induced oxidative stress in neurodegenerative disorders and aging Mutation Research 2009 674 1-2 73 84
48. Mller T., Muhlack S., Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients Movement Disorders 2011 26 3 543 546
49. Mller T., Jugel C., Ehret R., Ebersbach G., Bengel G., Muhlack S., Klostermann F., Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel Journal of Neural Transmission 2011 118 9 1329 1333
50. Schapira A. H. V., Present and future drug treatment for Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry 2005 76 11 1472 1478 (Pubitemid 41531688)
51. Barnham K. J., Masters C. L., Bush A. I., Neurodegenerative diseases and oxidatives stress Nature Reviews Drug Discovery 2004 3 3 205 214 (Pubitemid 38379987)
52. Mytilineou C., Kramer B. C., Yabut J. A., Glutathione depletion and oxidative stress Parkinsonism and Related Disorders 2002 8 6 385 387 (Pubitemid 36151653)
53. Roberts R. A., Smith R. A., Safe S., Szabo C., Tjalkens R. B., Robertson F. M., Toxicological and pathophysiological roles of reactive oxygen and nitrogen species Toxicology 2010 276 2 85 94
54. Stefanoni G., Sala G., Tremolizzo L., Rana A. Q., Alpha-synuclein, oxidative stress and autophagy failure: dangerous liaisons in dopaminergic neurodegeneration Etiology and Pathophysiology of Parkinson's Disease 2011 InTech
55. Crabtree D. M., Zhang J., Genetically engineered mouse models of Parkinson's disease. Brain Research Bulletin. In press
56. Lotharius J., Brundin P., Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein Nature reviews. Neuroscience 2002 3 12 932 942
57. Schapira A. H., Mitochondrial pathology in Parkinson's disease Mount Sinai Journal of Medicine 2011 78 6 872 881
58. Schapira A. H. V., Gegg M., Mitochondrial contribution to parkinson's disease pathogenesis Parkinson's Disease 2011 2011 7
59. Chaturvedi R. K., Beal M. F., Mitochondrial approaches for neuroprotection Annals of the New York Academy of Sciences 2008 1147 395 412
60. Swerdlow R. H., Parks J. K., Miller S. W., Origin and functional consequences of the complex I defect in Parkinson's disease Annals of Neurology 1996 40 4 663 671 (Pubitemid 26357892)
61. Fulda S., Galluzzi L., Kroemer G., Targeting mitochondria for cancer therapy Nature Reviews Drug Discovery 2010 9 6 447 464
62. Dumont M., Beal M. F., Neuroprotective strategies involving ROS in Alzheimer disease Free Radical Biology and Medicine 2011 51 5 1014 1026
63. Abou-Sleiman P. M., Muqit M. M. K., Wood N. W., Expanding insights of mitochondrial dysfunction in Parkinson's disease Nature Reviews Neuroscience 2006 7 3 207 219 (Pubitemid 43292466)
64. Petko J. A., Kabbani N., Frey C., Woll M., Hickey K., Craig M., Canfield V. A., Levenson R., Proteomic and functional analysis of NCS-1 binding proteins reveals novel signaling pathways required for inner ear development in zebrafish BMC Neuroscience 2009 10, article 27
65. Gandhi S., Wood-Kaczmar A., Yao Z., Plun-Favreau H., Deas E., Klupsch K., Downward J., Latchman D. S., Tabrizi S. J., Wood N. W., Duchen M. R., Abramov A. Y., PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death Molecular Cell 2009 33 5 627 638
66. Block M. L., Zecca L., Hong J. S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nature Reviews Neuroscience 2007 8 1 57 69 (Pubitemid 46011999)
67. Ceulemans A. G., Zgavc T., Kooijman R., Hachimi-Idrissi S., Sarre S., Michotte Y., The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia Journal of Neuroinflammation 2010 7, article 74
68. Chéret C., Gervais A., Lelli A., Colin C., Amar L., Ravassard P., Mallet J., Cumano A., Krause K. H., Mallat M., Neurotoxic activation of microglia is promoted by a Nox1-dependent NADPH oxidase Journal of Neuroscience 2008 28 46 12039 12051
69. Whitton P. S., Inflammation as a causative factor in the aetiology of Parkinson's disease British Journal of Pharmacology 2007 150 8 963 976 (Pubitemid 46628616)
70. Long-Smith C. M., Sullivan A. M., Nolan Y. M., The influence of microglia on the pathogenesis of Parkinson's disease Progress in Neurobiology 2009 89 3 277 287
71. Qian L., Flood P. M., Hong J. S., Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy Journal of Neural Transmission 2010 117 8 971 979
72. Beckman J. S., Beckman T. W., Chen J., Marshall P. A., Freeman B. A., Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide Proceedings of the National Academy of Sciences of the United States of America 1990 87 4 1620 1624
73. Mnzel T., Keaney J. F., Are ACE inhibitors a magic bullet against oxidative stress? Circulation 2001 104 13 1571 1574 (Pubitemid 32917353)
74. Anantharam V., Kaul S., Song C., Kanthasamy A., Kanthasamy A. G., Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells NeuroToxicology 2007 28 5 988 997 (Pubitemid 47519806)
75. Mertens B., Vanderheyden P., Michotte Y., Sarre S., The role of the central renin-angiotensin system in Parkinson's disease Journal of the Renin-Angiotensin-Aldosterone System 2010 11 1 49 56
76. Mertens B., Varcin M., Michotte Y., Sarre S., The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death European Journal of Neuroscience 2011 34 7 1141 1148
77. Perry V. H., Nicoll J. A. R., Holmes C., Microglia in neurodegenerative disease Nature Reviews Neurology 2010 6 4 193 201
78. Dawson T. M., Dawson V. L., Molecular pathways of neurodegeneration in Parkinson's disease Science 2003 302 5646 819 822 (Pubitemid 37339614)
79. Davies K. J. A., Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems IUBMB Life 2000 50 4-5 279 289 (Pubitemid 32289086)
80. Finkel T., Holbrook N. J., Oxidants, oxidative stress and the biology of ageing Nature 2000 408 6809 239 247
81. Clark J., Simon D. K., Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in parkinson's disease Antioxidants and Redox Signaling 2009 11 3 509 528
82. Scandalios J. G., Oxidative stress: molecular perception and transduction of signals triggering antioxidant gene defenses Brazilian Journal of Medical and Biological Research 2005 38 7 995 1014 (Pubitemid 41078961)
83. Calabrese V., Guagliano E., Sapienza M., Panebianco M., Calafato S., Puleo E., Pennisi G., Mancuso C., Allan Butterfield D., Stella A. G., Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes Neurochemical Research 2007 32 4-5 757 773 (Pubitemid 46481305)
84. Twig G., Elorza A., Molina A. J. A., Mohamed H., Wikstrom J. D., Walzer G., Stiles L., Haigh S. E., Katz S., Las G., Alroy J., Wu M., Py B. F., Yuan J., Deeney J. T., Corkey B. E., Shirihai O. S., Fission and selective fusion govern mitochondrial segregation and elimination by autophagy EMBO Journal 2008 27 2 433 446 (Pubitemid 351161653)
85. Tatsuta T., Langer T., Quality control of mitochondria: protection against neurodegeneration and ageing EMBO Journal 2008 27 2 306 314 (Pubitemid 351161660)
86. Vives-Bauza C., Przedborski S., Mitophagy: the latest problem for Parkinson's disease Trends in Molecular Medicine 2011 17 3 158 165
87. Youle R. J., Narendra D. P., Mechanisms of mitophagy Nature Reviews Molecular Cell Biology 2011 12 1 9 14
88. Beal M. F., Parkinson's disease: a model dilemma Nature 2010 466 7310 S8 S10
89. Melrose H. L., Lincoln S. J., Tyndall G. M., Farrer M. J., Parkinson's disease: a rethink of rodent models Experimental Brain Research 2006 173 2 196 204 (Pubitemid 44264883)
90. Duty S., Jenner P., Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease British Journal of Pharmacology 2011 164 4 1357 1391
91. Gama Sosa M. A., de Gasperi R., Elder G. A., Modeling human neurodegenerative diseases in transgenic systems Human Genetics 2012 131 4 535 563
92. Fernandes C., Rao Y., Genome-wide screen for modifiers of Parkinson's disease genes in Drosophila Molecular Brain 2011 4 1, article 17
93. Chen L., Cagniard B., Mathews T., Jones S., Koh H. C., Ding Y., Carvey P. M., Ling Z., Kang U. J., Zhuang X., Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice Journal of Biological Chemistry 2005 280 22 21418 21426 (Pubitemid 40805706)
94. Andres-Mateos E., Perier C., Zhang L., Blanchard-Fillion B., Greco T. M., Thomas B., Han S. K., Sasaki M., Ischiropoulos H., Przedborski S., Dawson T. M., Dawson V. L., DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase Proceedings of the National Academy of Sciences of the United States of America 2007 104 37 14807 14812 (Pubitemid 350003224)
95. Yamaguchi H., Shen J., Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-I-deficient mice Molecular Neurodegeneration 2007 2 1, article 10
96. Guzman J. N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P. T., Surmeier D. J., Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 Nature 2010 468 7324 696 700
97. Irrcher I., Aleyasin H., Seifert E. L., Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics Human Molecular Genetics 2010 19 19 3734 3746
98. Perez F. A., Curtis W. R., Palmiter R. D., Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity BMC Neuroscience 2005 6, article 71
99. Itier J. M., Ibez P., Mena M. A., Abbas N., Cohen-Salmon C., Bohme G. A., Laville M., Pratt J., Corti O., Pradier L., Ret G., Joubert C., Periquet M., Araujo F., Negroni J., Casarejos M. J., Canals S., Solano R., Serrano A., Gallego E., Snchez M., Denfle P., Benavides J., Tremp G., Rooney T. A., Brice A., Garca de Yébenes J., Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse Human Molecular Genetics 2003 12 18 2277 2291 (Pubitemid 37160872)
100. Palacino J. J., Sagi D., Goldberg M. S., Krauss S., Motz C., Wacker M., Klose J., Shen J., Mitochondrial dysfunction and oxidative damage in parkin-deficient mice Journal of Biological Chemistry 2004 279 18 18614 18622 (Pubitemid 38623283)
101. Periquet M., Corti O., Jacquier S., Brice A., Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function Journal of Neurochemistry 2005 95 5 1259 1276 (Pubitemid 41779252)
102. Rodrguez-Navarro J. A., Casarejos M. J., Menéndez J., Solano R. M., Rodal I., Gmez A., Yébenes J. G. D., Mena M. A., Mortality, oxidative stress and tau accumulation during ageing in parkin null mice Journal of Neurochemistry 2007 103 1 98 114 (Pubitemid 47404223)
103. Lu X. H., Fleming S. M., Meurers B., Ackerson L. C., Mortazavi F., Lo V., Hernandez D., Sulzer D., Jackson G. R., Maidment N. T., Chesselet M. F., Yang X. W., Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase k-resistant -Synuclein Journal of Neuroscience 2009 29 7 1962 1976
104. Akundi R. S., Huang Z., Eason J., Pandya J. D., Zhi L., Cass W. A., Sullivan P. G., Beler H., Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice PLoS ONE 2011 6 1
105. Billia F., Hauck L., Konecny F., Rao V., Shen J., Mak T. W., PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function Proceedings of the National Academy of Sciences of the United States of America 2011 108 23 9572 9577
106. Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., Ferrante R. J., Kowall N. W., Abeliovich A., Beal M. F., Mice lacking alpha-synuclein are resistant to mitochondrial toxins Neurobiology of Disease 2006 21 3 541 548 (Pubitemid 43277537)
107. Neumann M., Kahle P. J., Giasson B. I., Ozmen L., Borroni E., Spooren W., Mller V., Odoy S., Fujiwara H., Hasegawa M., Iwatsubo T., Trojanowski J. Q., Kretzschmar H. A., Haass C., Misfolded proteinase K-resistant hyperphosphorylated -synuclein in aged transgenic mice with locomotor deterioration and in human -synucleinopathies Journal of Clinical Investigation 2002 110 10 1429 1439 (Pubitemid 35396914)
108. Poon H. F., Frasier M., Shreve N., Calabrese V., Wolozin B., Butterfield D. A., Mitochondrial associated metabolic proteins are selectively oxidized in A30P -synuclein transgenic micea model of familial Parkinson's disease Neurobiology of Disease 2005 18 3 492 498 (Pubitemid 40332708)
109. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q., Lee V. M. Y., Neuronal -synucleinopathy with severe movement disorder in mice expressing A53T human -synuclein Neuron 2002 34 4 521 533 (Pubitemid 34628750)
110. Martin L. J., Pan Y., Price A. C., Sterling W., Copeland N. G., Jenkins N. A., Price D. L., Lee M. K., Parkinson's disease -synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death Journal of Neuroscience 2006 26 1 41 50 (Pubitemid 43089519)
111. Miller R. M., Kiser G. L., Kaysser-Kranich T., Casaceli C., Colla E., Lee M. K., Palaniappan C., Federoff H. J., Wild-type and mutant -synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD Experimental Neurology 2007 204 1 421 432 (Pubitemid 46343728)
112. Koob A. O., Ubhi K., Paulsson J. F., Kelly J., Rockenstein E., Mante M., Adame A., Masliah E., Lovastatin ameliorates -synuclein accumulation and oxidation in transgenic mouse models of -synucleinopathies Experimental Neurology 2010 221 2 267 274
113. Brandis K. A., Holmes I. F., England S. J., Sharma N., Kukreja L., DebBurman S. K., -synuclein fission yeast model: concentration-dependent aggregation without plasma membrane localization or toxicity Journal of Molecular Neuroscience 2006 28 2 179 192 (Pubitemid 43780330)
114. Perez F. A., Palmiter R. D., Parkin-deficient mice are not a robust model of parkinsonism Proceedings of the National Academy of Sciences of the United States of America 2005 102 6 2174 2179 (Pubitemid 40262031)
115. Kitada T., Pisani A., Karouani M., Haburcak M., Martella G., Tscherter A., Platania P., Wu B., Pothos E. N., Shen J., Impaired dopamine release and synaptic plasticity in the striatum of Parkin-/- mice Journal of Neurochemistry 2009 110 2 613 621
116. Son J. H., Kawamata H., Yoo M. S., Kim D. J., Lee Y. K., Kim S. Y., Dawson T. M., Zhang H., Sulzer D., Yang L., Beal M. F., Degiorgio L. A., Chun H. S., Baker H., Peng C., Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons Journal of Neurochemistry 2005 94 4 1040 1053 (Pubitemid 41170591)
117. Sato S., Chiba T., Nishiyama S., Kakiuchi T., Tsukada H., Hatano T., Fukuda T., Yasoshima Y., Kai N., Kobayashi K., Mizuno Y., Tanaka K., Hattori N., Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography Journal of Neuroscience Research 2006 84 6 1350 1357 (Pubitemid 44654458)
118. Von Coelln R., Thomas B., Savitt J. M., Lim K. L., Sasaki M., Hess E. J., Dawson V. L., Dawson T. M., Loss of locus coeruleus neurons and reduced startle in parkin null mice Proceedings of the National Academy of Sciences of the United States of America 2004 101 29 10744 10749 (Pubitemid 38955813)
119. Wang X., Winter D., Ashrafi G., PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility Cell 2011 147 4 893 906
120. Morais V. A., Verstreken P., Roethig A., Smet J., Snellinx A., Vanbrabant M., Haddad D., Frezza C., Mandemakers W., Vogt-Weisenhorn D., Van Coster R., Wurst W., Scorrano L., De Strooper B., Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function EMBO Molecular Medicine 2009 1 2 99 111
121. Kitada T., Pisani A., Porter D. R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E. N., Shen J., Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice Proceedings of the National Academy of Sciences of the United States of America 2007 104 27 11441 11446 (Pubitemid 47175159)
122. Gispert S., Ricciardi F., Kurz A., Azizov M., Hoepken H. H., Becker D., Voos W., Leuner K., Mller W. E., Kudin A. P., Kunz W. S., Zimmerman A., Roeper J., Wenzel D., Jendrach M., Garca-Arencbia M., Fernndez-Ruiz J., Huber L., Rohrer H., Barrera M., Reichert A. S., Rb U., Chen A., Nussbaum R. L., Auburger G., Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration PLoS ONE 2009 4 6
123. Zhou H., Falkenburger B. H., Schulz J. B., Tieu K., Xu Z., Xu G. X., Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice International Journal of Biological Sciences 2007 3 4 242 250 (Pubitemid 46425506)
124. Mills R. D., Sim C. H., Mok S. S., Mulhern T. D., Culvenor J. G., Cheng H. C., Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1) Journal of Neurochemistry 2008 105 1 18 33 (Pubitemid 351441646)
125. Wood-Kaczmar A., Gandhi S., Yao Z., Abramov A. S. Y., Miljan E. A., Keen G., Stanyer L., Hargreaves I., Klupsch K., Deas E., Downward J., Mansfield L., Jat P., Taylor J., Heales S., Duchen M. R., Latchman D., Tabrizi S. J., Wood N. W., PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons PLoS ONE 2008 3 6
126. Gegg M. E., Cooper J. M., Schapira A. H. V., Taanman J. W., Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in DOPAMINERGIC cells PLoS ONE 2009 4 3
127. Kabbani N., Negyessy L., Lin R., Goldman-Rakic P., Levenson R., Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor Journal of Neuroscience 2002 22 19 8476 8486 (Pubitemid 35387588)
128. Pongs O., Lindemeier J., Zhu X. R., Theil T., Engelkamp D., Krah-Jentgens I., Lambrecht H. G., Koch K. W., Schwemer J., Rivosecchi R., Mallart A., Galceran J., Canal I., Barbas J. A., Ferrus A., Frequenina novel calcium-binding protein that modulates synaptic efficacy in the Drosophila nervous system Neuron 1993 11 1 15 28 (Pubitemid 23222530)
129. Hatano T., Kubo S. I., Sato S., Hattori N., Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease Journal of Neurochemistry 2009 111 5 1075 1093
130. Pogson J. H., Ivatt R. M., Whitworth A. J., Molecular mechanisms of PINK1-related neurodegeneration Current Neurology and Neuroscience Reports 2011 11 3 283 290
131. Pilsl A., Winklhofer K. F., Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease Acta Neuropathologica 2012 2 173 188
132. Narendra D. P., Jin S. M., Tanaka A., Suen D. F., Gautier C. A., Shen J., Cookson M. R., Youle R. J., PINK1 is selectively stabilized on impaired mitochondria to activate Parkin PLoS Biology 2010 8 1
133. Kitada T., Tong Y., Gautier C. A., Shen J., Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice Journal of Neurochemistry 2009 111 3 696 702
134. Klein J. A., Ackerman S. L., Oxidative stress, cell cycle, and neurodegeneration Journal of Clinical Investigation 2003 111 6 785 793 (Pubitemid 37074950)
135. Hatano T., Hattori N., Rana A. Q., Etiology and pathogenesis of Parkinsons disease Etiology and Pathophysiology of Parkinson's Disease 2011 InTech
136. Chade A. R., Kasten M., Tanner C. M., Nongenetic causes of Parkinson's disease Journal of Neural Transmission 2006 70, supplement 147 151 (Pubitemid 44622192)
137. Marques S. C., Oliveira C. R., Pereira C. M., Outeiro T. F., Epigenetics in neurodegeneration: a new layer of complexity Progress in Neuro- Psychopharmacology Biological Psychiatry 2011 35 2 348 355
138. Babenko O., Kovalchuk I., Metz G. A., Epigenetic programming of neurodegenerative diseases by an adverse environment Brain Research 2012 1444 96 111
139. Blandini F., Armentero M. T., Martignoni E., The 6-hydroxydopamine model: news from the past Parkinsonism and Related Disorders 2008 14 2 S124 S129
140. Kim R. H., Smith P. D., Aleyasin H., Hayley S., Mount M. P., Pownall S., Wakeham A., You-Ten A. J., Kalia S. K., Horne P., Westaway D., Lozano A. M., Anisman H., Park D. S., Mak T. W., Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress Proceedings of the National Academy of Sciences of the United States of America 2005 102 14 5215 5220
141. Manning-Bog A. B., Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter Neurobiology of Disease 2007 27 2 141 150 (Pubitemid 47088976)
142. Paterna J. C., Leng A., Weber E., Feldon J., Beler H., DJ-1 and parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice Molecular Therapy 2007 15 4 698 704 (Pubitemid 46431989)
143. Zhou H., Huang C., Tong J., Xia X. G., Early exposure to paraquat sensitizes dopaminergic neurons to subsequent silencing of PINK1 gene expression in mice International Journal of Biological Sciences 2011 7 8 1180 1187
144. Haque M. E., Thomas K. J., D'Souza C., Callaghan S., Kitada T., Slack R. S., Fraser P., Cookson M. R., Tandon A., Park D. S., Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP Proceedings of the National Academy of Sciences of the United States of America 2008 105 5 1716 1721 (Pubitemid 351346580)
145. Dauer W., Kholodilov N., Vila M., Trillat A. C., Goodchild R., Larsen K. E., Staal R., Tieu K., Schmitz Y., Yuan C. A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., Hen R., Resistance of -synuclein null mice to the parkinsonian neurotoxin MPTP Proceedings of the National Academy of Sciences of the United States of America 2002 99 22 14524 14529 (Pubitemid 35257704)
146. Schlter O. M., Fornai F., Alessandr M. G., Takamori S., Geppert M., Jahn R., Sdhof T. C., Role of -synuclein in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinsonism in mice Neuroscience 2003 118 4 985 1002 (Pubitemid 36561187)
147. Drolet R. E., Behrouz B., Lookingland K. J., Goudreau J. L., Mice lacking -synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration NeuroToxicology 2004 25 5 761 769 (Pubitemid 39013325)
148. Robertson D. C., Schmidt O., Ninkina N., Jones P. A., Sharkey J., Buchman V. L., Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of -synuclein, -synuclein and double / -synuclein null mutant mice Journal of Neurochemistry 2004 89 5 1126 1136 (Pubitemid 38715830)
149. Fornai F., Schlter O. M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C. L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Sdhof T. C., Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and -synuclein Proceedings of the National Academy of Sciences of the United States of America 2005 102 9 3413 3418 (Pubitemid 40328059)
150. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Hglinger G. U., Oertel W. H., Hartmann A., Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and -synuclein-deleted mice Experimental Neurology 2008 210 1 182 193 (Pubitemid 351265366)
151. Rathke-Hartlieb S., Kahle P. J., Neumann M., Ozmen L., Haid S., Okochi M., Haass C., Schulz J. B., Sensitivity to MPTP is not increased in Parkinson' s disease-associated mutant -synuclein transgenic mice Journal of Neurochemistry 2001 77 4 1181 1184 (Pubitemid 32467072)
152. Nieto M., Gil-Bea F. J., Dalf E., Cuadrado M., Cabodevilla F., Snchez B., Catena S., Sesma T., Ribé E., Ferrer I., Ramrez M. J., Gmez-Isla T., Increased sensitivity to MPTP in human -synuclein A30P transgenic mice Neurobiology of Aging 2006 27 6 848 856
153. Dong Z., Ferger B., Feldon J., Beler H., Overexpression of Parkinson's disease-associated -synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP Journal of Neurobiology 2002 53 1 1 10
154. Yu W. H., Matsuoka Y., Szirki I., Hashim A., LaFrancois J., Sershen H., Duff K. E., Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2, 3,6- tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T -synuclein Neurochemical Research 2008 33 5 902 911
155. Peng J., Oo M. L., Andersen J. K., Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration Journal of Neurochemistry 2010 115 6 1363 1373
156. Gao H. M., Zhang F., Zhou H., Kam W., Wilson B., Hong J. S., Neuroinflammation and -synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease Environmental Health Perspectives 2011 119 6 807 814
157. Fernagut P. O., Hutson C. B., Fleming S. M., Tetreaut N. A., Salcedo J., Masliah E., Chesselet M. F., Behavioral and histopathological consequences of paraquat intoxication in mice: effects of -synuclein over-expression Synapse 2007 61 12 991 1001 (Pubitemid 350271779)
158. Richfield E. K., Thiruchelvam M. J., Cory-Slechta D. A., Wuertzer C., Gainetdinov R. R., Caron M. G., Di Monte D. A., Federoff H. J., Behavioral and neurochemical effects of wild-type and mutated human -synuclein in transgenic mice Experimental Neurology 2002 175 1 35 48 (Pubitemid 34507908)
159. Thiruchelvam M. J., Powers J. M., Cory-Slechta D. A., Richfield E. K., Risk factors for dopaminergic neuron loss in human -synuclein transgenic mice European Journal of Neuroscience 2004 19 4 845 854 (Pubitemid 38297021)
160. Filipov N. M., Norwood A. B., Sistrunk S. C., Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent NeuroReport 2009 20 7 713 717
161. Grealish S., Mattsson B., Draxler P., Bjrklund A., Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease European Journal of Neuroscience 2010 31 12 2266 2278
162. Iancu R., Mohapel P., Brundin P., Paul G., Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice Behavioural Brain Research 2005 162 1 1 10 (Pubitemid 40726275)
163. Schwarting R. K., Sedelis M., Hofele K., Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease Neurotoxicity Research 1999 1 1 41 56
164. Sedelis M., Hofele K., Auburger G. W., Morgan S., Huston J. P., Schwarting R. K. W., MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences Behavior Genetics 2000 30 3 171 182
165. Lee M., Hyun D. H., Halliwell B., Jenner P., Effect of the overexpression of wild-type or mutant -synuclein on cell susceptibility to insult Journal of Neurochemistry 2001 76 4 998 1009 (Pubitemid 32167373)
166. Orth M., Tabrizi S. J., Tomlinson C., Messmer K., Korlipara L. V. P., Schapira A. H. V., Cooper J. M., G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage Neurochemistry International 2004 45 5 669 676 (Pubitemid 38844888)
167. Hamza T. H., Chen H., Hill-Burns E. M., Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee PLoS Genetics 2011 7 8
168. Lewitt P., Recent advances in CSF biomarkers for Parkinson's disease Parkinsonism Related Disorders 2012 18, supplement 1 S49 S51
169. van Dijk K. D., Teunissen C. E., Drukarch B., Jimenez C. R., Groenewegen H. J., Berendse H. W., van de Berg W. D. J., Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach Neurobiology of Disease 2010 39 3 229 241
170. Gerlach M., Maetzler W., Broich K., Hampel H., Rems L., Reum T., Riederer P., Stffler A., Streffer J., Berg D., Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics Journal of Neural Transmission 2011 119 1 39 52
171. Alberio T., Fasano M., Proteomics in Parkinson's disease: an unbiased approach towards peripheral biomarkers and new therapies Journal of Biotechnology 2011 156 4 325 337
172. Helmich R. C., Mark H., Deuschl G., Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain. In press
173. Van Rooden S. M., Colas F., Martnez-Martn P., Visser M., Verbaan D., Marinus J., Chaudhuri R. K., Kok J. N., Van Hilten J. J., Clinical subtypes of Parkinson's disease Movement Disorders 2011 26 1 51 58